Dividend/Distribution - CYC  
 
    Initial Director's Interest Notice  
 
    CYC Board Changes  
 
    Cyclopharm USFDA Update  
 
    Ceasing to be a substantial holder from MUFG  
 
    Ceasing to be a substantial holder from MS  
 
    Becoming a substantial holder from MUFG  
 
    Becoming a substantial holder from MS  
 
    Ceasing to be a substantial holder from MUFG  
 
    Ceasing to be a substantial holder from MS  
 
    Becoming a substantial holder from MUFG  
 
    Becoming a substantial holder from MS  
 
    Ceasing to be a substantial holder from MUFG  
 
    Ceasing to be a substantial holder from MS  
 
    Becoming a substantial holder from MUFG  
 
    Becoming a substantial holder from MS  
 
    Ceasing to be a substantial holder from MUFG  
 
    Ceasing to be a substantial holder from MS  
 
    Becoming a substantial holder from MUFG  
 
    Becoming a substantial holder from MS  
 
    Ceasing to be a substantial holder from MUFG  
 
    Ceasing to be a substantial holder from MS  
 
    Becoming a substantial holder from MUFG  
 
    Becoming a substantial holder from MS  
 
    Ceasing to be a substantial holder from MUFG  
 
    Ceasing to be a substantial holder from MS  
 
    Becoming a substantial holder from MUFG  
 
    Ceasing to be a substantial holder from MUFG  
 
    Becoming a substantial holder from MS  
 
    CYC Amended Constitution  
 
    Results of Meeting  
 
    Becoming a substantial holder from MUFG  
 
    Ceasing to be a substantial holder from MUFG  
 
    Managing Director's Address to Shareholders  
 
    CYC 2021 AGM Presentation  
 
    Chairman's Address to Shareholders  
 
    Ceasing to be a substantial holder from MS  
 
    Becoming a substantial holder from MS  
 
    Ceasing to be a substantial holder from MS  
 
    Becoming a substantial holder from MUFG  
 
    Becoming a substantial holder from MS  
 
    Ceasing to be a substantial holder from MUFG  
 
    Ceasing to be a substantial holder from MS  
 
    Becoming a substantial holder from MUFG  
 
    Becoming a substantial holder from MS  
 
    Notice of Annual General Meeting/Proxy Form  
 
    Appendix 4G  
 
    Change of Share Registry Details  
 
    S&P DJI Announces March 2021 Quarterly Rebalance  
 
    Confirmation of Technegas USFDA Timetable  
 
    Change of Director's Interest Notice - DH  
 
    Change of Director's Interest Notice - TM  
 
    Date of Annual General Meeting  
 
    Dividend/Distribution - CYC  
 
    Change of Director's Interest Notice DH  
 
    Change of Director's Interest Notice TM  
 
    Appendix 2A LTIP  
 
    Appendix 2A SPP  
 
    Appendix 3B - Amended  
 
    Cyclopharm Announces Results of Share Purchase Plan Offer  
 
    Change in substantial holding - Chemical Overseas  
 
    Change in substantial holding - Barings  
 
    Change in substantial holding  
 
    Change in substantial holding from CVC  
 
    Change of substantial shareholding from AEF  
 
    Share Purchase Plan Offer Booklet  
 
    Appendix 2A - Placement  
 
    Cleansing Notice - Share Purchase Plan  
 
    Cleansing Notice - Placement  
 
    Change in substantial holding  
 
    Change in substantial shareholding from AEF  
 
    Proposed issue of Securities - CYC  
 
    Cyclopharm Capital Raising Presentation  
 
    Cyclopharm Successfully Completes A$30 Million Placement  
 
    SNMMI Requests USFDA to Expedite Approval For Technegas  
 
    Trading Halt  
 
    USFDA Approval Progress for Technegas and Business Update  
 
    Bell Potter Healthcare Conference  
 
    Change of Director's Interest Notice TM  
 
    Change of Director's Interest Notice  
 
    Change of Director's Interest Notice  
 
    Cyclopharm Investor Presentation  
 
    Technegas USA Trial Successfully Meets Primary Endpoint  
 
    CYC Partners With McMasters University In COVID-19 Research  
 
    Dividend/Distribution - CYC  
 
    Change of Director's Interest Notice  
 
    Appendix 2A  
 
    Results of Meeting  
 
    Managing Director's Address to Shareholders  
 
    CYC 2020 AGM Presentation  
 
    Chairman's Address to Shareholders  
 
    Notice of Annual General Meeting/Proxy Form  
 
    Technegas Approved in Russia - Clarification  
 
    USFDA Approval to File Received for Technegas  
 
    Technegas Approved in Russia  
 
    Final share buy-back notice - Appendix 3F  
 
    Form 484 cancellation of Long Term Incentive Plan shares  
 
    Appendix 2A  
 
    USFDA Grants Cyclopharm USD$2.9m Application Fee Waiver  
 
    CYC Appendix 4G  
 
    Cyclopharm Lodges NDA for Technegas with the USFDA  
 
    Cyclopharm Company Update  
 
    Change of Director's Interest Notice  
 
    Change of Director's Interest Notice  
 
    Change of Director's Interest Notice  
 
    Cyclopharm Investor Presentation  
 
    Change of Director's Interest Notice  
 
    Dividend/Distribution - CYC  
 
    Change in substantial holding  
 
    Change in substantial holding  
 
    Change in substantial holding  
 
    Becoming a substantial holder  
 
    Change in substantial holding from CVC  
 
    Change in substantial holding from AEF  
 
    Becoming a substantial holder  
 
    Appendix 3B  
 
    Change of Director's Interest Notice  
 
    CYC Institutional Placement - Premium To Share Price  
 
    AGREEMENT TO UTILISE CYCLOTRON FACILITY ASSETS  
 
    Trading Halt  
 
    Pause in Trading  
 
    Appendix 3B  
 
    Change of Director's Interest Notice JM  
 
    Appendix 3B  
 
    Final Director's Interest Notice  
 
    Board Update  
 
    Cyclopharm Investor Presentation - TechKnow Invest Roadshow  
 
    Cyclopharm Strengthens Leadership Team  
 
    Dividend/Distribution - CYC  
 
    Cyclopharm Investor Presentation - Bioshares 2019  
 
    Change of Director's Interest Notice - TM  
 
    Change of Director's Interest Notice - TM  
 
    Appendix 3B LTIP  
 
    Change of Director's Interest Notice  
 
    Appendix 3B  
 
    Announcement of buy-back - Appendix 3C  
 
    Results of Meeting  
 
    Managing Director's Address to Shareholders  
 
    CYC 2019 AGM Presentation  
 
    Chairman's Address to Shareholders  
 
    Final share buy-back notice - Appendix 3F  
 
    Notice of General Meeting/Proxy Form  
 
    Cyclopharm Investor Presentation  
 
    Change of Director's Interest Notice  
 
    CYC Appendix 4G  
 
    Annual Report to shareholders  
 
    Dividend/Distribution - CYC  
 
    CYC - FNN Interview  
 
    Positive USFDA Meeting - Technegas sales expected in 2019  
 
    CYC Form 484 Cancellation of Long Term Incentive Plan shares  
 
    Change of Director's Interest Notice VG  
 
    Response to ASX Appendix 3Y Query  
 
    Change of Director's Interest Notice VG  
 
    Cyclopharm FNN Investor Event  
 
    Dividend/Distribution - CYC  
 
    Change in substantial holding from CVC  
 
    Change in substantial holding from AEF  
 
    Appendix 3B LTIP  
 
    Change of Director's Interest Notice  
 
    Change of Director's Interest Notice - Amended  
 
    Change of Director's Interest Notice  
 
    Change in substantial holding from CVC  
 
    Change in substantial holding from AEF  
 
    Announcement of buy-back - Appendix 3C  
 
    Results of Meeting  
 
    CYC 2018 AGM Presentation  
 
    Managing Director's Address to Shareholders  
 
    Chairman's Address to Shareholders  
 
    Final share buy-back notice - Appendix 3F  
 
    Better Defining Airways Disease with Technegas  
 
    Cyclopharm Acquires Scandinavian Distribution Business  
 
    Notice of Annual General Meeting/Proxy Form  
 
    40 Patient Milestone Achieved For Technegas USFDA Trial  
 
    CYC Appendix 4G  
 
    2017 Results Presentation  
 
    Change of Director's Interest Notice - David Heaney  
 
    Dividend/Distribution - CYC  
 
    FNN Interview and Presentation  
 
    Cyclopharm FNN Investor Event  
 
    Change of Director's Interest Notice - D Heaney